The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | OESIRI-PRODIGE 62: Nal-IRI with 5-FU versus paclitaxel in metastatic ESCC
David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, comments the Phase II OESIRI-PRODIGE 62 trial (NCT03719924) of nanoliposomal irinotecan (Nal-IRI) with 5-fluorouracil versus paclitaxel as second-line treatment in patients with metastatic esophageal squamous cell carcinoma (mESCC) following progression after platinum-based therapies. The primary endpoint, overall survival at 9 months, was not met and both arms showed low efficacy. While paclitaxel demonstrated a better safety profile, more patients experienced quality-of-life deterioration in both groups, warranting further exploration of treatment options. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
